$15.7 M

CTRV Mkt cap, 22-Jun-2018
ContraVir Pharmaceuticals Net income (Q1, 2018)-2.7 M
ContraVir Pharmaceuticals EBIT (Q1, 2018)-3.9 M
ContraVir Pharmaceuticals Cash, 31-Mar-20184 M

ContraVir Pharmaceuticals Financials

ContraVir Pharmaceuticals Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016

R&D expense

15 m

General and administrative expense

5.8 m

Operating expense total

20.8 m

EBIT

(140.2 k)(14 m)(20.8 m)

Interest expense

328 12.9 k

Net Income

(140.5 k)(14.3 m)(17 m)

Quarterly

USDQ1, 2016Q2, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q1, 2018

R&D expense

3.8 m4 m3.1 m4.3 m2.9 m4 m2.3 m

General and administrative expense

1.1 m1.5 m1.7 m1.7 m2 m1.9 m1.6 m

Operating expense total

4.8 m5.5 m4.9 m6 m4.9 m5.8 m3.9 m

Depreciation and amortization

6 k

EBIT

(4.8 m)(5.5 m)(4.9 m)(6 m)(4.9 m)(5.8 m)(3.9 m)

Pre tax profit

(6.4 m)(7.6 m)(3.2 m)

Income tax expense

1.9 m1.9 m536 k

Net Income

(4.8 m)(3 m)(4.8 m)(4.5 m)(7.6 m)(5.8 m)(2.7 m)

ContraVir Pharmaceuticals Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

1.8 m4.6 m7.4 m6 m

Accounts Receivable

Inventories

Current Assets

2 m5.2 m7.9 m6.1 m

PP&E

14.5 k81.4 k80.8 k56.6 k

Goodwill

1.9 m1.9 m

Total Assets

2 m5.4 m13.1 m11.3 m

Accounts Payable

243.9 k1.5 m4.3 m1.6 m

Short-term debt

Current Liabilities

458.7 k1.9 m5.1 m2.6 m

Long-term debt

Total Liabilities

11.8 m7.5 m

Additional Paid-in Capital

2.5 m17.4 m32.2 m69.7 m

Retained Earnings

(5.4 m)(27.6 m)(44.6 m)(67 m)

Total Equity

(2.9 m)3.4 m1.3 m3.7 m

Financial Leverage

-0.7 x1.6 x9.9 x3 x

Quarterly

USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q1, 2018

Cash

3 m10.6 m6.1 m8.8 m4 m

Current Assets

3.6 m10.9 m6.6 m8.9 m4.1 m

PP&E

73.8 k80 k71.6 k61.6 k46.4 k

Goodwill

1.9 m1.9 m1.9 m1.9 m1.9 m

Total Assets

8.8 m16.1 m11.8 m14.1 m9.4 m

Accounts Payable

4.4 m2.3 m1.6 m1.5 m1.7 m

Current Liabilities

5.2 m3.2 m2.5 m2.8 m2.6 m

Total Liabilities

9.1 m6.3 m

Additional Paid-in Capital

44.6 m58.6 m60.1 m69.2 m71.7 m

Retained Earnings

(49.4 m)(53.9 m)(61.6 m)(65.3 m)(69.7 m)

Total Equity

5.9 m(385.4 k)5 m3.1 m

Financial Leverage

2.7 x-30.5 x2.8 x3.1 x

ContraVir Pharmaceuticals Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016

Net Income

(140.5 k)(14.3 m)(17 m)

Depreciation and Amortization

16.4 k21.5 k

Accounts Payable

3.1 m

Cash From Operating Activities

(13.3 k)(9.7 m)(16.6 m)

Purchases of PP&E

(83.3 k)(6.6 k)

Cash From Investing Activities

(83.3 k)(502.2 k)

Cash From Financing Activities

100 k12.5 m19.9 m

Interest Paid

12.9 k

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

(4.8 m)(3 m)(4.8 m)(4.5 m)(7.6 m)(2.7 m)

Depreciation and Amortization

4.9 k

Accounts Payable

213.3 k114.4 k1.3 m3.2 m3.2 m3.4 m4.4 m2.3 m1.6 m146 k

Cash From Operating Activities

(3.6 m)

Cash From Investing Activities

900

Cash From Financing Activities

1.6 m

ContraVir Pharmaceuticals Ratios

USDY, 2018

Financial Leverage

3.1 x
Report incorrect company information